Sickle cell R&D hit by three culls in one day at Novartis/Intellia, Sangamo and Graphite Bio
Three biotechs disclosed pullbacks on sickle cell disease R&D in the span of 16 hours: with Graphite Bio ending work, Sangamo Therapeutics searching for a program partner and Intellia Therapeutics saying Novartis reneged on an early-phase clinical trial.
The pipeline rewrites come as Vertex and partner CRISPR Therapeutics wrap up an approval request for their ex vivo gene-edited therapy and as bluebird bio sends in the paperwork for an FDA green light of its gene therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.